Please login to the form below

Not currently logged in
Email:
Password:

New faces at Open Plan

UK consultancy recruits two new research team members
Open Plan Neil Rees

Open Plan, a division of Open Health and Chime Insight and Engagement, has hired Neil Rees as head of research and Catherine Swanson as a senior research executive.

Both roles are new, and necessary, Open Health partner Cory Inglis told PMLiVE, because “the aim is to grow the research division”.

Rees (top right) joins from Kadence International where he was head of qualitative research, working across B2B, B2C and healthcare sectors. He will be responsible for the management, development and growth of the Open Plan team, all of whom will report to him. 

Swanson (bottom right) joins Open Plan from Kantar Health. Following a PhD in Chemistry at the University of Manchester, Swanson worked for Kantar Health in Shanghai before returning to the UK. She works on qualitative and quantitative methodologies across a variety of therapy areas.

Open Plan Catherine Swanson"Both appointments add to the breadth of experience of our team. This enables us to meet a variety of research challenges to support our client brand teams,” said Inglis.

“I am very optimistic for the growth of OPEN Plan. The team have delivered some fantastic projects for our clients that really drive their brand's understanding,” he added.

Crispin Beale, chief executive of Chime Insight & Engagement, added: “I'm delighted to welcome Neil and Katherine to the Chime team – both are real experts in their field and further strengthen our team, allowing us to serve our rapidly growing client base.”

4th February 2014

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...